NxStage Medical (NASDAQ:NXTM) Receiving Somewhat Positive Press Coverage, Accern Reports
Media headlines about NxStage Medical (NASDAQ:NXTM) have trended somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. NxStage Medical earned a media sentiment score of 0.12 on Accern’s scale. Accern also assigned media stories about the medical device company an impact score of 45.5575933323801 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- Eagle Asset Management Inc Raises Its Position in NxStage Medical, Inc. (NXTM) (leisuretravelaid.com)
- Updates on Most Active Stock: Nxstage Medical Inc (NXTM) (fishinghd.com)
- NxStage Medical, Inc. (NXTM) Position Decreased by Nationwide Fund Advisors Last Quarter (techkenyot.com)
- NxStage Kidney Care and Dialyze Direct to Provide On-Site Dialysis to Skilled Nursing Facility Patients in Ohio (finance.yahoo.com)
- NxStage Medical, Inc. – Value Analysis (NASDAQ:NXTM) : August 12, 2017 (finance.yahoo.com)
Several equities analysts have commented on NXTM shares. Northland Securities cut NxStage Medical from an “outperform” rating to a “market perform” rating in a report on Thursday, May 4th. BidaskClub raised NxStage Medical from a “hold” rating to a “buy” rating in a report on Friday, June 30th. William Blair cut NxStage Medical from an “outperform” rating to a “market perform” rating in a report on Monday, August 7th. BTIG Research reaffirmed a “buy” rating and issued a $27.00 price target on shares of NxStage Medical in a report on Wednesday, May 10th. Finally, Jefferies Group LLC cut NxStage Medical from a “buy” rating to a “hold” rating and cut their price target for the company from $33.00 to $30.00 in a report on Tuesday. One research analyst has rated the stock with a sell rating and eight have issued a hold rating to the stock. The company has an average rating of “Hold” and a consensus target price of $30.29.
NxStage Medical (NASDAQ NXTM) traded down 0.20% during trading on Friday, reaching $29.22. The company’s stock had a trading volume of 1,627,197 shares. NxStage Medical has a 52-week low of $20.45 and a 52-week high of $30.80. The firm’s 50-day moving average is $24.92 and its 200-day moving average is $25.85. The stock’s market cap is $1.93 billion.
NxStage Medical (NASDAQ:NXTM) last announced its quarterly earnings data on Monday, August 7th. The medical device company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). NxStage Medical had a negative net margin of 1.33% and a negative return on equity of 2.43%. The business had revenue of $92.20 million during the quarter, compared to the consensus estimate of $96.47 million. During the same period in the previous year, the business earned ($0.03) earnings per share. The company’s revenue was up .0% on a year-over-year basis. Equities research analysts forecast that NxStage Medical will post ($0.04) EPS for the current year.
In other NxStage Medical news, President Joseph E. Turk, Jr. sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 5th. The shares were sold at an average price of $25.19, for a total transaction of $25,190.00. Following the completion of the transaction, the president now directly owns 75,903 shares in the company, valued at $1,911,996.57. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Matthew W. Towse sold 4,300 shares of the business’s stock in a transaction that occurred on Monday, May 22nd. The shares were sold at an average price of $21.36, for a total transaction of $91,848.00. Following the transaction, the senior vice president now owns 29,637 shares of the company’s stock, valued at $633,046.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 53,900 shares of company stock valued at $1,404,073. Company insiders own 4.70% of the company’s stock.
About NxStage Medical
NxStage Medical, Inc is a medical technology company. The Company develops, manufactures and markets products and services for patients suffering from chronic or acute kidney failure. It operates through three segments. The System One segment includes revenues from the sale and rental of the System One and PureFlow SL dialysate preparation equipment and the sale of disposable products in the home and critical care markets.
Receive News & Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.